Hims & Novo Call a Truce, Hims Gets Exactly What It Wanted

Core Insights - Hims & Hers and Novo Nordisk have resolved their patent infringement lawsuit, opting for a partnership that allows Hims to sell Novo's branded drugs Ozempic and Wegovy at competitive prices [2][3] - Hims' stock surged nearly 50% following the announcement, indicating strong market reaction to the news [3] - The agreement includes Hims ceasing the advertisement of compounded GLP-1 drugs and limiting their use to clinically necessary cases [4] Company Developments - Hims had previously sold a compounded version of Wegovy, which led to legal action from Novo, but the new partnership marks a significant shift in their relationship [3][5] - Novo's CEO expressed confidence that the litigation will not be reopened, suggesting a definitive resolution to the conflict [4] - Hims' CEO is now focusing on adapting to a "rapidly shifting landscape" and exploring new therapies for their platform, framing the partnership as a growth strategy [6] Industry Context - The U.S. patent for Semaglutide, the active ingredient in Ozempic and Wegovy, is valid until 2032, and regulatory changes are tightening loopholes for compounding [6] - Novo has resolved its supply shortages, which previously allowed Hims to exploit legal gaps in the market [6]